Imiquimod nanostructured-lipid-carrier topical patch

Technology
Conceptual
University
Scouted & summarized by Halo AI

The Imiquimod nanostructured-lipid-carrier (NLC) topical patch is a novel, optimized drug delivery system developed by the University of South Australia. By utilizing NLC technology within a matrix-type patch, it significantly improves imiquimod deposition in deeper skin layers compared to traditional creams, offering a promising alternative for treating skin cancers like basal cell carcinoma with enhanced patient compliance.

Overview

The Imiquimod nanostructured-lipid-carrier (NLC) topical patch is a novel drug delivery system developed by researchers at the University of South Australia. It is designed to improve the treatment of skin conditions such as superficial basal cell carcinoma and actinic keratosis. By incorporating imiquimod-loaded NLCs into a matrix-type topical patch, this technology addresses the limitations of conventional imiquimod creams, which often suffer from poor skin permeation, local toxicity, and reduced patient compliance.

Technical specifications
  • Formulation: Utilizes nanostructured lipid carriers (NLCs) composed of stearyl alcohol, oleic acid, Tween 80, and Gelucire 50/13.
  • Delivery Mechanism: The NLCs are incorporated into a hydroxypropyl methylcellulose (HPMC) K4M matrix-type patch.
  • Performance: The patch significantly enhances drug deposition into deeper skin layers, specifically the dermis, compared to commercial creams.
  • Optimization: Developed using a hybrid design of experiments (DoE) approach, including 2k factorial and central composite designs, to optimize particle size, polydispersity index, and zeta potential.
  • Characteristics: The optimized NLCs feature an average particle size of 75.6 nm, a polydispersity index of 0.235, and a zeta potential of –30.9 mV.
Technology readiness level

The technology is at a research and development stage (TRL 3-4). It has been successfully developed, optimized, and characterized in a laboratory setting, with ex vivo permeation studies demonstrating superior performance compared to commercial products. It has not yet reached clinical trials or commercial deployment.

Generated Oct 8, 2026. Please verify key information.

About University of South Australia

Formerly a comprehensive public research university based in Adelaide, UniSA operated multiple city and regional campuses; operations transitioned to the new Adelaide University on January 1, 2026, with an official opening on January 29, 2026. For industry, a one‑stop Enterprise Hub streamlined access to consulting, testing and bespoke training. Co‑located facilities in Adelaide BioMed City (including the UniSA Cancer Research Institute/Bradley Building) enabled close links with hospital partners, while the Mawson Lakes campus adjoined Technology Park to anchor defence and advanced‑technology collaborations. Research was consistently supported by competitive national funding from the Australian Research Council and the National Health and Medical Research Council, often alongside matched industry support. Commercialisation was backed by a dedicated technology transfer function and the Innovation & Collaboration Centre’s incubation and acceleration programs.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.